AI Summary & Key Takeaways
AI InsightTo obtain better results, a BRS with good radial strength, thinner strut thickness, and rapid deployment should be achieved.
📌 3 Key Takeaways
Abstract
A bioresorbable scaffold (BRS) has been used in the latest stages of stent technology and is a less-known material than drug-eluting stents (DES). In this study, we aimed to evaluate the long-term clinical outcomes of BRS in patients presenting with non-ST-segment elevation myocardial infarction (NSTEMI), a type of acute coronary syndrome (ACS). 39 patients and 53 lesions who applied to Istanbul Medipol University Faculty of Medicine Hospital between June 2015 and April 2016 with a diagnosis of NSTEMI and were treated with BRS were included in the study. The 4-year follow-up of the patients between 2016 and 2020 was recorded. Endpoints for the study were device success, treatment success, stent thrombosis, restenosis, and major adverse cardiac events (MACE). Operations were performed with a device success rate of 98.1% and a treatment success rate of 98.1%. No death or stent thrombosis was detected in any patient, and target lesion revascularization (TLR) occurred in one patient. The total rate of MACE was found to be 1.9%. Complications developed in two patients during the procedure and hospitalization and in four patients during the 4-year follow-up. If BRS are implanted by experienced surgeons in NSTEMI patients, it has been observed that the complication rate in the early period is low, and the complication rate increases depending on the type of stent chosen in the late period. To obtain better results, a BRS with good radial strength, thinner strut thickness, and rapid deployment should be achieved.